Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese - PubMed (original) (raw)
Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese
Keitaro Matsuo et al. Cancer Sci. 2007 Jan.
Abstract
The present study aimed to assess the impact of smoking and sex for the risk of non-small-cell lung cancer (NSCLC) with or without epidermal growth factor receptor (EGFR) mutation. We conducted a case-control study using 152 patients with EGFR-mutated (EGFRmut) NSCLC, 283 with EGFR-wild-type (EGFRwt) NSCLC and 2175 age- and sex-frequency-matched controls. Smoking was a significant risk factor for EGFRwt NSCLC (odds ratio [OR] for ever-smokers, 4.05; 95% confidence interval [CI], 2.79-5.88) but not for EGFRmut NSCLC (OR, 0.73; CI, 0.46-1.14). Sex did not affect this association. The association was observed consistently with other smoking-related parameters including pack-years. Sex was the sole risk factor for EGFRmut NSCLC (OR for women relative to men, 2.19; CI, 1.41-3.39) and there was no significant interaction between women and smoking. In contrast, sex, smoking and their interaction were significant in EGFRwt NSCLC. The impact of sex on EGFR mutation status was assessed by several indicators of reproductive history among women. Total fertile years showed a significant positive association with EGFRmut NSCLC but not with EGFRwt NSCLC. Other indicators showed similar trends and this result may partly explain the sexual difference in the acquisition of EGFR mutation. In conclusion, our case-control study clearly demonstrated that the impacts of smoking and sex on the risk of EGFRmut NSCLC are different from those for EGFRwt NSCLC. Further epidemiological evaluation is warranted.
Similar articles
- TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Wei R, Cao L, Pu H, Wang H, Zheng Y, Niu X, Weng X, Zhang H, Favus M, Zhang L, Jia W, Zeng Y, Amos CI, Lu S, Wang HY, Liu Y, Liu W. Wei R, et al. Clin Cancer Res. 2015 Nov 15;21(22):5173-5180. doi: 10.1158/1078-0432.CCR-15-0009. Epub 2015 Jul 6. Clin Cancer Res. 2015. PMID: 26149460 Free PMC article. - Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, Chewaskulyong B, Sunpaweravong P, Ohe Y, Ichinose Y, Yang JJ, Mok TS, Young H, Haddad V, Rukazenkov Y, Fukuoka M. Wu YL, et al. Lung Cancer. 2017 Feb;104:119-125. doi: 10.1016/j.lungcan.2016.11.022. Epub 2016 Nov 30. Lung Cancer. 2017. PMID: 28212993 Clinical Trial. - Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC. Lee CK, et al. J Natl Cancer Inst. 2013 May 1;105(9):595-605. doi: 10.1093/jnci/djt072. Epub 2013 Apr 17. J Natl Cancer Inst. 2013. PMID: 23594426 Review. - First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA. Greenhalgh J, et al. Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Cochrane Database Syst Rev. 2016. PMID: 27223332 Updated. Review.
Cited by
- Menstrual factors, reproductive factors and lung cancer risk: a meta-analysis.
Zhang Y, Yin Z, Shen L, Wan Y, Zhou B. Zhang Y, et al. Zhongguo Fei Ai Za Zhi. 2012 Dec;15(12):701-19. doi: 10.3779/j.issn.1009-3419.2012.12.04. Zhongguo Fei Ai Za Zhi. 2012. PMID: 23249716 Free PMC article. - Identification of prognostic markers of lung cancer through bioinformatics analysis and in vitro experiments.
Ling B, Liao X, Huang Y, Liang L, Jiang Y, Pang Y, Qi G. Ling B, et al. Int J Oncol. 2020 Jan;56(1):193-205. doi: 10.3892/ijo.2019.4926. Epub 2019 Nov 28. Int J Oncol. 2020. PMID: 31789390 Free PMC article. - Lung cancers unrelated to smoking: characterized by single oncogene addiction?
Suda K, Tomizawa K, Yatabe Y, Mitsudomi T. Suda K, et al. Int J Clin Oncol. 2011 Aug;16(4):294-305. doi: 10.1007/s10147-011-0262-y. Epub 2011 Jun 8. Int J Clin Oncol. 2011. PMID: 21655907 - Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic management of lung cancer patients.
Hashimoto N, Matsuzaki A, Okada Y, Imai N, Iwano S, Wakai K, Imaizumi K, Yokoi K, Hasegawa Y. Hashimoto N, et al. BMC Pulm Med. 2014 Feb 5;14:14. doi: 10.1186/1471-2466-14-14. BMC Pulm Med. 2014. PMID: 24498965 Free PMC article. - Molecular epidemiology of female lung cancer.
Yim SH, Chung YJ. Yim SH, et al. Cancers (Basel). 2011 Apr 1;3(2):1861-76. doi: 10.3390/cancers3021861. Cancers (Basel). 2011. PMID: 24212786 Free PMC article.
References
- Travis WD, Colby TV, Corrin B, Shimosato Y, Brabilla E, Sobin LH. Histological Typing of Lung and Pleural Tumours, 3rd edn. Berlin: Springer, 1999.
- Hunter T, Cooper JA. Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells. Cell 1981; 24: 741–52. - PubMed
- Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 (Suppl. 4): S9–15. - PubMed
- Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002; 29 (5 Suppl. 14): 3–9. - PubMed
- Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non‐small cell lung cancer. Semin Oncol 2002; 29 (5 Suppl. 14): 38–44. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous